Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022

Background: Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy. Objective: This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres-Canchala, Laura, Cleves-Luna, Daniela, Arias-Valderrama, Oriana, Candelo, Estephania, Guerra, María Angelica, Pachajoa, Harry, Olaya, Manuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856545/
https://www.ncbi.nlm.nih.gov/pubmed/36670605
http://dx.doi.org/10.3390/children10010054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856545/
https://www.ncbi.nlm.nih.gov/pubmed/36670605
http://dx.doi.org/10.3390/children10010054

Ejemplares similares